TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10919420

Group type: EXPERIMENTAL
Intervention: Sedated patients (Study A)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Nonsedated patients (Study A)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Group A (no supplementary oxygen, Study B)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Group B (0 min pre-oxygenation, Study B)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Group C (2 min pre-oxygenation, Study B)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Group D (5 min pre-oxygenation, Study B)
Number of subjects: 220
Study: 8724448

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.1 mg, 0.25 mg, 0.5 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1314536

Group type: EXPERIMENTAL
Intervention: Live-attenuated vaccine (28,000 pfu, 2800 pfu, or 280 pfu of Oka/Merck strain virus)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Heat-inactivated vaccine (comparable antigen content to live vaccine)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High-dose groups (greater than or equal to 7.1 antigen units)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Lowest dose (less than or equal to 0.71 antigen units)
Number of subjects: 95
Study: 2864890

Group type: EXPERIMENTAL
Intervention: Procaterol hydrochloride tablet formulation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Procaterol hydrochloride syrup formulation
Number of subjects: 11
Study: 31826893

Group type: EXPERIMENTAL
Intervention: Telephone coaching (education session + 8 sessions over 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (education session only)
Number of subjects: 72
Study: 29040663

Group type: EXPERIMENTAL
Intervention: hsTnT and H-FABP measured at 0, 4, 6, and 24 hours post PCI
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: hsTnT and H-FABP at 4 hours post PCI
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Follow-up for major adverse clinical events (MACE) at 1 year
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: hsTnT and H-FABP
Number of subjects: 209
Study: 27102843

Group type: EXPERIMENTAL
Intervention: Extended-field irradiation (EFI)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Pelvic only radiotherapy (PRT)
Number of subjects: 116
Study: 24201305

Group type: EXPERIMENTAL
Intervention: FuFIRI
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: mIROX
Number of subjects: 423
Study: 22003819

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotripsy (PCNL)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 64
Study: 20175876

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 2399
Study: 18019664

Group type: EXPERIMENTAL
Intervention: Immodin (IM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 45
Study: 16145697

Group type: EXPERIMENTAL
Intervention: Computerized visual incentives (CVI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Spirometry without CVI
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Spirometry with CVI
Number of subjects: 47
Study: 11876665

Group type: EXPERIMENTAL
Intervention: Videotape only (15 groups)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Videotape plus skills instruction (18 groups)
Number of subjects: 75
Study: 10541304

Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary analyses of the MDRD Study
Number of subjects: 0
Study: 8886347

Group type: EXPERIMENTAL
Intervention: Energy + micronutrient supplementation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Micronutrient alone
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 2062510

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg per day)
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Early argon laser photocoagulation
Number of subjects: 3711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3711

Group type: COMPARATOR
Intervention: Deferral of photocoagulation
Number of subjects: 3711
Study: 6129797

Group type: EXPERIMENTAL
Intervention: Regimen I (glutamate 1.5 mmol/kg/day and aspartate 1.0 mmol/kg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Regimen II (no glutamate and aspartate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal, orally fed premature infants
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Regimen I and II
Number of subjects: 8
Study: 31031463

Group type: EXPERIMENTAL
Intervention: Primaquine (PQ)
Number of subjects: 53
Study: 28967485

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 370
Study: 26311100

Group type: EXPERIMENTAL
Intervention: Intra-articular dexmedetomidine (2 μg/kg body weight) and ropivacaine (18 mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intra-articular dexmedetomidine (1 μg/kg body weight) and ropivacaine (18 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-articular ropivacaine (20 mL)
Number of subjects: 60
Study: 23567483

Group type: EXPERIMENTAL
Intervention: 0.1 μg/kg/min remifentanil infusion (Group R1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg/min remifentanil infusion (Group R2)
Number of subjects: 70
Study: 20518009

Group type: EXPERIMENTAL
Intervention: Chronic total occlusion (CTO) group
Number of subjects: 1071
Study: 18454862

Group type: EXPERIMENTAL
Intervention: Walnut supplement (75 g/d)
Number of subjects: 21
Study: 16567267

Group type: EXPERIMENTAL
Intervention: High-dose thiamine (250 mg/day) and pyridoxine (200 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15050679

Group type: EXPERIMENTAL
Intervention: Asked for a collateral and provided one
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asked for a collateral but did not provide one
Number of subjects: 0
Study: 11063954

Group type: EXPERIMENTAL
Intervention: Current smokers of > or = 20 cigarettes per day
Number of subjects: 21068

Group type: EXPERIMENTAL
Intervention: Current smokers of <20 cigarettes per day
Number of subjects: 21068

Group type: EXPERIMENTAL
Intervention: Past smokers
Number of subjects: 21068

Group type: EXPERIMENTAL
Intervention: Current smokers of > or = 20 cigarettes per day (after multivariate adjustment)
Number of subjects: 21068

Group type: EXPERIMENTAL
Intervention: Current smokers of <20 cigarettes per day (after multivariate adjustment)
Number of subjects: 21068

Group type: EXPERIMENTAL
Intervention: Past smokers (after multivariate adjustment)
Number of subjects: 21068

Group type: EXPERIMENTAL
Intervention: Total pack‐years of cigarette smoking
Number of subjects: 21068
Study: 9057634

Group type: EXPERIMENTAL
Intervention: Aggressive transfusion (group 1, 110 patients)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Conservative transfusion (group 2, 120 patients)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Nontransfusion (group 3, 37 patients)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Nonrandomized transfusion (group 4, 97 patients)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Open cholecystectomy
Number of subjects: 364
Study: 8334805

Group type: EXPERIMENTAL
Intervention: Intra-observer repeatability
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Between-observer repeatability
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long-term repeatability
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spontaneous evolution over 8 hours
Number of subjects: 30
Study: 3094617

Group type: EXPERIMENTAL
Intervention: Lipid-based TPN regimen (Intralipid providing 50% of calorific requirement)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Carbohydrate-based TPN regimen (control)
Number of subjects: 23
Study: 3189208

Group type: EXPERIMENTAL
Intervention: Village health program
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: High-calorie snacks
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Vitamin-mineral supplements
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11000
Study: 31664766

Group type: EXPERIMENTAL
Intervention: BOS161721 (1-240 mg, intravenous and subcutaneous doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOS161721 (subcutaneous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOS161721
Number of subjects: 0
Study: 30475457

Group type: EXPERIMENTAL
Intervention: Behavioral Activation System (BAS)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Behavioral Inhibition System (BIS)
Number of subjects: 53
Study: 28477860

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 13400

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 13400

Group type: COMPARATOR
Intervention: Normal weight group (reference)
Number of subjects: 13400

Group type: EXPERIMENTAL
Intervention: Overweight group
Number of subjects: 13400
Study: 25142280

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (grade 5 strength)
Number of subjects: 130
Study: 23906160

Group type: EXPERIMENTAL
Intervention: Clinical risk variables and PlGF measurement
Number of subjects: 3529

Group type: EXPERIMENTAL
Intervention: Clinical risk variables
Number of subjects: 3529

Group type: COMPARATOR
Intervention: Control group (n=188)
Number of subjects: 3529
Study: 20191568

Group type: EXPERIMENTAL
Intervention: 28-joint count (JC28)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 32-joint count (JC32)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 36-joint count (JC36)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Logistic regression for ACR20 response
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: American College of Rheumatology (ACR) responses
Number of subjects: 182
Study: 17940553

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 0
Study: 16970214

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/d) added to ongoing statin therapy for 6 weeks
Number of subjects: 3030

Group type: COMPARATOR
Intervention: Placebo added to ongoing statin therapy for 6 weeks
Number of subjects: 3030
Study: 15595305

Group type: EXPERIMENTAL
Intervention: 70% VO2(peak)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 50% VO2(peak)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 11385384

Group type: EXPERIMENTAL
Intervention: Acetylcholine (10(‐8), 10(‐7), 10(‐6), and 10(‐5) mol/L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 and 1.0 microg. kg(‐1). min(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acetylcholine (Control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitroglycerin (Control)
Number of subjects: 10
Study: 9524875

Group type: EXPERIMENTAL
Intervention: Equivalent Scores (ES) standardized tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Battery of 10 ES-standardized tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General indications concerning normality threshold
Number of subjects: 0
Study: 8281589

Group type: EXPERIMENTAL
Intervention: Full lateral position
Number of subjects: 88

Group type: COMPARATOR
Intervention: Wedged supine position
Number of subjects: 88
Study: 3105681

Group type: EXPERIMENTAL
Intervention: Pinch skin grafts
Number of subjects: 53

Group type: COMPARATOR
Intervention: Porcine dermis
Number of subjects: 53
Study: 30094437

Group type: EXPERIMENTAL
Intervention: Oat protein (25 g protein) for 19 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 19 days
Number of subjects: 0
Study: 26803276

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 117
Study: 24920942

Group type: EXPERIMENTAL
Intervention: Coload (15 ml/kg of crystalloid after intrathecal injection)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preload (15 ml/kg of crystalloid before intrathecal injection)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coload
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preload
Number of subjects: 60
Study: 22419728

Group type: EXPERIMENTAL
Intervention: 4 mg iv zoledronate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 20641122

Group type: EXPERIMENTAL
Intervention: Postconditioning (PC)
Number of subjects: 43
Study: 19370949

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endotracheal Intubation
Number of subjects: 200
Study: 15936878

Group type: EXPERIMENTAL
Intervention: Depressed subjects
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study: 14517524

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (0.35 mg/kg/d) and/or prednisolone (2 mg/kg/day)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 11933340

Group type: EXPERIMENTAL
Intervention: Charing Cross system (CX4L)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Modified Charing Cross system (Parema)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Robinson Ultra Four (Robinson)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Overall healing rates
Number of subjects: 149
Study: 9504181

Group type: EXPERIMENTAL
Intervention: NaF treatment (0.02%, 0.05% or 0.1%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (other mouthrinses containing xylitol, sorbitol, sacarine, ciclamate, aspartame, chlorhexidine, hexetidine)
Number of subjects: 0
Study: 8368193

Group type: EXPERIMENTAL
Intervention: Brief lecture dispelling myths about hypnosis and modified HGSHS:A
Number of subjects: 687

Group type: COMPARATOR
Intervention: Standard version of HGSHS:A
Number of subjects: 687
Study: 2878675

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Nifedipine and Metoprolol combined
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Nifedipine (in patients pretreated with a beta blocker)
Number of subjects: 515
Study: 31698917

Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal cell (ASC) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28453471

Group type: EXPERIMENTAL
Intervention: ELND005 (scyllo-Inositol) 250 mg twice daily (BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ELND005 (scyllo-Inositol) 250 mg once daily (QD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24047539

Group type: EXPERIMENTAL
Intervention: Aflibercept combined with FOLFIRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI + placebo
Number of subjects: 0
Study: 21045172

Group type: EXPERIMENTAL
Intervention: Whey (0.3 g/kg lean body mass)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Casein (0.3 g/kg lean body mass)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (noncaloric drink)
Number of subjects: 17
Study: 19681415

Group type: EXPERIMENTAL
Intervention: Ketamine pre-treatment (10 mg in 1.0 ml saline) under tourniquet for 30 seconds before propofol injection.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Ketamine added to propofol (10 mg in 9 ml propofol mixed with 1.0 ml saline).
Number of subjects: 188
Study: 16696744

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 mug daily self-injection for a median of 19 months, with daily oral supplements of 1,000 mg calcium and 400 to 1,200 IU vitamin D.
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1085
Study: 12955294

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 11397884

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Raloxifene (both doses)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9777817

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Incorrect treatment for renin profile but correct for age-race subgroup
Number of subjects: 1105
Study: 7889894

Group type: EXPERIMENTAL
Intervention: K‐85 2 g twice daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: Corn oil 2 g twice daily (placebo)
Number of subjects: 95
Study: 3065571

Group type: EXPERIMENTAL
Intervention: Clonidine 0.125% eye drops
Number of subjects: 20
Study: 31732234

Group type: EXPERIMENTAL
Intervention: Active intervention group (n=35)
Number of subjects: 71
Study: 30453950

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri V3401 (5 × 10^9 CFU daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28157261

Group type: EXPERIMENTAL
Intervention: MG-assisted TSP
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional fluoroscopically guided TSP
Number of subjects: 31
Study: 25286887

Group type: EXPERIMENTAL
Intervention: Endurance training (five sessions over two weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sub-groups of the training group (3000 meter group, 4x4-minutes high-intensity interval group, continuous training group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Baseline running performance
Number of subjects: 36
Study: 23129021

Group type: EXPERIMENTAL
Intervention: Online
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Resources
Number of subjects: 159

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 159
Study: 21273603

Group type: EXPERIMENTAL
Intervention: CCND1 rs9344 genotype (G allele carriers: GG or AG)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group (AA wild-type genotype)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: CCND1 rs9344 genotype
Number of subjects: 620
Study: 19484585

Group type: EXPERIMENTAL
Intervention: Mammotome system
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Vacora system
Number of subjects: 233
Study: 16968574

Group type: EXPERIMENTAL
Intervention: Trazodone prolonged-release 150-450 mg/day (n = 62)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sertraline 50-100 mg/day (n = 60)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Trazodone prolonged-release
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 122
Study: 15351368

Group type: EXPERIMENTAL
Intervention: Motor evoked potential (MEP) study
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potential (SEP) study
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of MEP and SEP
Number of subjects: 39
Study: 11049800

Group type: EXPERIMENTAL
Intervention: Oral miltefosine, 50 mg given twice daily for 14 days (group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral miltefosine, 50 mg given twice daily for 21 days (group B)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral miltefosine, 50 mg given twice daily for 28 days (group C)
Number of subjects: 54
Study: 9272591

Group type: EXPERIMENTAL
Intervention: C-peptide infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (without C-peptide)
Number of subjects: 7
Study: 7618720

Group type: EXPERIMENTAL
Intervention: 2.5 mg of bupivacaine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 10 micrograms of sufentanil
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2.5 mg of bupivacaine plus 10 micrograms of sufentanil
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2.5 mg of bupivacaine and 10 micrograms of sufentanil
Number of subjects: 52
Study: 2144206

Group type: EXPERIMENTAL
Intervention: Zoladex depot supplemented by flutamide 250 mg 3 qid
Number of subjects: 327

Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 327
Study: 318577

Group type: EXPERIMENTAL
Intervention: Liquid antacid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31585971

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered wound assessment tool in addition to standard postoperative care
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 500
Study: 28283485

Group type: EXPERIMENTAL
Intervention: QUIT EMR score (Quality of interhospital critical care transportation)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: SEMROS (Simplified EMR outcome score)
Number of subjects: 3000
Study: 26161601

Group type: EXPERIMENTAL
Intervention: Hybrid Composite Resin (HCR)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Resin Modified Glass Ionomer Cement (RMGIC)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Giomer Composite Resin (GCR)
Number of subjects: 41
Study: 24935051

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO(3); TUMS(®))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (HCl; Renagel(®))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pantoprazole sodium (Protonix(®))
Number of subjects: 0
Study: 22038523

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4‐8 mg/day
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30‐45 mg/day
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Vitamin D 1,000 IU/day
Number of subjects: 1332